Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Rigel Pharmaceuticals Inc maintains a gross margin of 93.16%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 40.91%, while the net margin is 40.17%. These profitability ratios, combined with a Return on Equity (ROE) of 220.06%, provide a clear picture of how effectively RIGL converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, RIGL competes directly with industry leaders such as LBRX and OCGN. With a market capitalization of $628.40M, it holds a significant position in the sector. When comparing efficiency, RIGL's gross margin of 93.16% stands against LBRX's N/A and OCGN's 100.00%. Such benchmarking helps identify whether Rigel Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
